Author

Donna M. Small

Queen's University BelfastORCID 0000-0001-8995-2590Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A.R. Phillips· 2 shared Connor N. BrowniD· 2 shared Daniel B. LongleyiD· 2 shared Emma M. KerriD· 2 shared Matilda Downs· 2 shared Aideen E. RyaniD· 1 shared Alice T. Browne· 1 shared Alyson SpeediD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A.R. Phillips

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 5, 2026

FLIP is essential for oncogenic KRAS-driven lung cancer

Claudia Hamilton, Shaun Sharkey, Hajrah A. Khawaja…·Daniel B. Longley

This study identifies FLIP as a critical survival factor in KRAS-mutant lung cancers, revealing a KRAS-ERK-FLIP axis that protects against apoptosis and suggests FLIP as a therapeutic target.

DOI 10.64898/2026.08.04.738686

mouseproteomics

𝕏 PostBluesky

Cancer BiologyCommunications BiologyPeer-reviewedMay 26, 2026

Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state

Shania M. Corry, Svetlana S. Sakhnevych, Noha Ehssan Mohamed…·Philip D. Dunne

This study shows that poly(I:C) treatment in CMS4 colorectal tumors induces a pro-inflammatory, CMS1-like regenerative state and identifies biomarkers for predicting therapeutic response.

DOI 10.1038/s42003-026-10295-9

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 9, 2026

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response

Alice T. Browne, Chris McCann, William J. McDaid…·Emma M. Kerr

This study shows that mutant KRAS dosage affects therapeutic response in lung cancer, with higher dosages linked to resistance to platinum therapy and sensitivity to pS6K inhibition.

DOI 10.64898/2026.05.06.723208

humanbulk RNA-seq

𝕏 PostBluesky